Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$502.12 13.79 (2.67)%

High 529.99 Low 500.74 Volume 1,447,343 Market Cap 52.41B
06/27/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jun 27

    Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

    Read on
  • Jun 22

    Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885)

    Read on

EVENTS

  • Goldman Sachs 38th Annual Global Healthcare Conference
    Jun 13, 2017 | 11:40 AM ET

  • Regeneron Corporate Presentation – June 2017
    Jun 13, 2017

Events & Presentations

NASDAQ REGN

$502.12 13.79 (2.67)%

High 529.99 Low 500.74 Volume 1,447,343 Market Cap 52.41B
06/27/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information